Handok, Novartis Korea strengthen strategic alliance

Published: 2010-02-22 06:56:00

Updated: 2010-02-22 06:56:00

Handok Pharm said it will co-market new oral treatment released by Novartis, called Galvusmet, a combination of vildagliptin and metformin, here in Korea.

To this end, Handok and Novartis Korea signed an agreement to jointly promote Galvusmet on February 17. Galvusmet has been marketed in 34 c...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK